Prof. Dr. Mahmoud Ghannoum, Case Western Reserve University and Universiy Hospitals Cleveland Medical Center and BIOHM HEALTH LLC, United States
Prof. Dr. Mahmoud Ghannoum, renowned for his contributions in Health Professions, is affiliated with Case Western Reserve University, University Hospitals Cleveland Medical Center, and BIOHM HEALTH LLC in the United States. His pioneering research focuses on microbiome dynamics and its impact on human health. Dr. Ghannoum’s work spans innovative approaches to understanding fungal communities and their therapeutic implications, shaping modern healthcare practices. With a distinguished career marked by groundbreaking discoveries, he continues to lead advancements in microbiology, fostering new insights into disease prevention and treatment. 🌿🔬 His collaborative efforts bridge academia and healthcare, paving the way for transformative medical solutions.
PROFILE 🌟
Googlescholar
EDUCATION 🎓
Prof. Dr. Mahmoud Ghannoum, based at the American University of Beirut, Lebanon, has a rich academic journey spanning multiple continents and disciplines. He earned his B.Sc. in 1973 from the American University of Beirut, followed by an M.Sc. and Ph.D. from Loughborough University of Technology, England, in 1974 and 1978, respectively. Dr. Ghannoum further enhanced his expertise with a Yeast Genetics Course at Cold Spring Harbor Laboratories in 1993. His commitment to leadership and management led him to complete an Executive MBA at Case Western Reserve University’s Weatherhead School of Management in 2004. 🎓✨
PROFESSIONAL EXPERIENCE 🌐
🎓 Prof. Dr. Mahmoud Ghannoum is a distinguished figure in medical mycology, currently serving as Tenured Professor in the Department of Dermatology at Case Western Reserve University since 2000. He is the Director of the Center for Medical Mycology and the Mycology Reference Laboratory at Case Western Reserve and University Hospitals Case Medical Center. With a background spanning from Kuwait University to UCLA School of Medicine, his career includes pivotal roles in microbiology and infectious diseases research. Prof. Ghannoum’s expertise bridges academia and clinical practice, shaping advancements in fungal research and treatment worldwide. 🌍🔬
PROFESSIONAL ACTIVITIES 🌐
🌐 Prof. Dr. Mahmoud Ghannoum has played a pivotal role in infectious disease research and dermatology at Case Western Reserve University. He chaired various committees, including the Dermatology Department’s Recruitment and Promotion Committee and the Antifungal Susceptibility Subcommittee of CLSI. His leadership extends to international conferences and editorial boards, enhancing medical mycology and antimicrobial research. As President of the Medical Mycological Society of Americas and advisor to CLSI’s Consensus Committee on Microbiology, his influence spans academia and clinical practice. With ongoing NIH involvement and numerous committee memberships, Prof. Ghannoum continues to shape global standards in infectious disease management and medical research.
TRANSLATIONAL RESEARCH 🧬
Prof. Dr. Mahmoud Ghannoum is a pioneer in biofilm research, co-founding Great Lakes Pharmaceuticals, Inc. and spearheading the development of B-lock™, an innovative antibiofilm product. Currently undergoing Phase III clinical trials via the 505(b)(2) regulatory pathway 🧪, B-lock™ shows promise in combating microbial biofilms. Dr. Ghannoum has also submitted multiple invention disclosures to Tech Transfer offices: one focusing on catheter Lock solutions for biofilm treatment 💡, another on the metabolomics profile of head and neck cancer 🧬, and a third on using Pichia as a probiotic or therapeutic against fungal infections 🍄. Additionally, he is involved in a patent application for photodynamic therapy 🌟, showcasing his commitment to advancing medical science.
ENTREPRENEURIAL ACTIVITIES 💼
Prof. Dr. Mahmoud Ghannoum, as Chief Scientific Officer and Co-Founder of Great Lakes Pharmaceuticals, spearheaded translational research leading to an anti-biofilm lock solution now in Phase III clinical trials, based on his RO1 on microbial biofilms 🧫. He conducted extensive pre-clinical studies and secured $2.7 million in Fast Track funding through SBIR grants 💡. Additionally, he played a pivotal role in raising private financing from angel investors and venture capital firms like Charter Life Science Fund 🌱. As Chief Scientific Officer of Oasis Consumer Healthcare LLC/ARMS Pharmaceutical, he oversaw the development of germ remediation drugs, managed Phase II trials, and facilitated nearly $8 million in private funding 🌍. His consultancy roles with major pharmaceutical companies underscore his profound impact on the industry 🔬.
PROFESSIONAL ASSOCIATIONS 🤝
Prof. Dr. Mahmoud Ghannoum is a distinguished member of several prestigious organizations, including the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), American Society for Microbiology, and Infectious Diseases Society of America, where he holds fellowship status. His expertise extends to the American Academy of Dermatology and the International Society for Human and Animal Mycology (ISHAM). He has previously been associated with the Leaders Society of the Dermatology Foundation and the Society for Investigative Dermatology (SID). Dr. Ghannoum’s contributions have also been recognized by the Society for General Microbiology (U.K.) and the American Association for the Advancement of Sciences. 🌍🔬👨🔬
HONORS AND SPECIAL AWARDS 🏅
Prof. Dr. Mahmoud Ghannoum has garnered extensive recognition for his pioneering contributions in microbiology and infectious diseases. He received the prestigious “Freedom to Discover Award” from Bristol Myers-Squibb, a testament to his groundbreaking research with a $500,000 grant. His intellectual achievements were further honored with the Kuwait Foundation for Advancement of Science Award, emphasizing scientific advancement. Dr. Ghannoum’s leadership includes chairing the Antifungal Sub-committee of the Clinical and Laboratory Standards Institute and serving as a member of NIH study sections. Named one of Cleveland’s “Most Interesting People,” he also received awards like the Billy Cooper Award and the Prevent Blindness America Investigator Award for his research on biofilms. 🏆🔬
PUBLICATIONS TOP NOTES 📚
Biofilm Formation by the Fungal PathogenCandida albicans: Development, Architecture, and Drug Resistance
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
Characterization of the oral fungal microbiome (mycobiome) in healthy individuals
Potential role of phospholipases in virulence and fungal pathogenesis
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole …
Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins
Antifungal resistance of candidal biofilms formed on denture acrylic in vitro
A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns
Comparison of Biofilms Formed by Candidaalbicans and Candidaparapsilosis on Bioprosthetic Surfaces
Antifungal susceptibility testing: practical aspects and current challenges